New-onset Refractory Status Epilepticus after BNT162b2 mRNA COVID-19 Vaccination

Author: Hyun Kyung KIM ¹ ; Ye Ji JANG ; Taeho SEO ; Yoo Jeong ROH ; Jung-Won SHIN
Author Information

1. Department of Neurology, CHA University Bundang Medical Center, CHA University, Seongnam, Korea
Publication Type:Case Report
From:Journal of the Korean Neurological Association 2023;41(3):204-209
CountryRepublic of Korea
Language:Korean
Abstract: Increasing importance of vaccination during coronavirus disease 2019 (COVID-19) pandemic, several vaccines were developed. Messenger RNA (mRNA) vaccines including BNT162b2 (Pfizer, New York, NY, USA; BioNTech, Mainz, Germany), mRNA-1273 (Moderna, Cambridge, MA, USA) have been disclosed side effects such as thrombocytopenia, myocarditis and headache in general. In addition, adverse effects due to autoimmune responses induced by spike glycoproteins of mRNA vaccines are rarely reported such as the Guillain-Barre syndrome, autoimmune encephalitis and so on. Herein, we report a rare case of encephalitis with new-onset refractory status epilepticus after BNT162b2 mRNA COVID-19 vaccination improved with immune therapy.